• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Godly gift for arthritis pain
Big Pharma is at it again… Creating and selling a drug that causes thousands of heart attacks and strokes each year. In 2015, the FDA asked drug makers to strengthen their warning labels. Since then, most have listed their dangerous side effects on the bottle. But one manufacturer thought they didn’t have to warn people about their dangerous drug. They marketed their product as a “unique” breakthrough. They even published studies promising it was “safe for long-term use.” 1 The drug is a 7-year-old arthritis drug called Actemra. It’s made by the Swiss pharmaceutical company Roche. ...
Source: Al Sears, MD Natural Remedies - October 5, 2017 Category: Complementary Medicine Authors: Al Sears Tags: Anti-Aging Source Type: news

Comparison of the risks of hospitalisation for cardiovascular events in patients with rheumatoid arthritis treated with tocilizumab and etanercept.
CONCLUSIONS: RA patients with TCZ do not have a medium-term excess of CV risk in patients compared with ETN. PMID: 29303702 [PubMed - as supplied by publisher]
Source: Clinical and Experimental Rheumatology - January 6, 2018 Category: Rheumatology Tags: Clin Exp Rheumatol Source Type: research

Cardiovascular Safety of Tocilizumab versus Tumor Necrosis Factor Inhibitors in Patients with Rheumatoid Arthritis – a Multi‐database Cohort Study
Conclusion: This multi‐database population‐based cohort study found no evidence of an increased CV risk among RA patients who switched from a different biologic drug or tofacitinib to TCZ versus to a TNFi. This article is protected by copyright. All rights reserved.
Source: Arthritis and Rheumatism - February 27, 2017 Category: Rheumatology Authors: Seoyoung C. Kim, Daniel H. Solomon, James R. Rogers, Sara Gale, Micki Klearman, Khaled Sarsour, Sebastian Schneeweiss Tags: Full Length Source Type: research

Adverse Events in Giant Cell Arteritis and Rheumatoid Arthritis Patient Populations: Analyses of Tocilizumab Clinical Trials and Claims Data
ConclusionHigher IRs of AESI were observed in patients with GCA versus those with RA in both TCZ-na ïve and -treated cohorts. Differences in underlying disease, age, and glucocorticoid use may influence AESI incidence, irrespective of intervention.FundingThis study was funded by F. Hoffmann-La Roche Ltd and Genentech, Inc. Article processing charges were funded by F. Hoffmann-La Roche Ltd.Plain Language SummaryPlain language summary is available for this article.
Source: Rheumatology and Therapy - February 1, 2019 Category: Rheumatology Source Type: research

Actemra Rheumatoid Arthritis Drug Tied to Significant Side Effects
Actemra, manufactured by Roche/Genentech, has been associated with heart attack, heart failure, stroke, pancreatitis, lung disease, gastrointestinal perforation, and more
Source: Disabled World - July 24, 2017 Category: Disability Tags: Pharmaceutical Source Type: news

Biological agents reduce cardiovascular events in rheumatoid arthritis non-responsive to tumor necrosis factor-inhibitors – a national cohort study
ConclusionsRA TNFi non-responder patients who received second line tocilizumab or abatacept had more benefit on CV events prevention compared with rituximab.
Source: Canadian Journal of Cardiology - January 16, 2020 Category: Cardiology Source Type: research

The risk of cardiovascular events associated with disease-modifying antirheumatic drugs in rheumatoid arthritis.
CONCLUSION: Abatacept and TNFi were associated with decreased risk of CVD compared to csDMARDs. Minimizing glucocorticoid use and optimizing MTX dose may improve CV outcomes in patients with RA. PMID: 32801134 [PubMed - as supplied by publisher]
Source: Journal of Rheumatology - August 18, 2020 Category: Rheumatology Tags: J Rheumatol Source Type: research

Cardiovascular events and change in cholesterol levels in patients with rheumatoid arthritis treated with tocilizumab: data from the REGATE Registry.
CONCLUSIONS: In current practice, cardiovascular events occurring under TCZ treatment is in the range of what is expected in RA patients despite a global increase in cholesterol levels. PMID: 32896267 [PubMed - as supplied by publisher]
Source: Clinical and Experimental Rheumatology - September 12, 2020 Category: Rheumatology Tags: Clin Exp Rheumatol Source Type: research

New Analyses Suggest Favorable Results for STELARA ® (ustekinumab) When Used as a First-Line Therapy for Bio-Naïve Patients with Moderately to Severely Active Crohn’s Disease and Ulcerative Colitis
SPRING HOUSE, PENNSYLVANIA, October 25, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from two new analyses of STELARA® (ustekinumab) for the treatment of adults with moderately to severely active Crohn’s disease (CD) and ulcerative colitis (UC).1,2 In a modelled analysisa focused on treatment sequencing using data from randomized controlled trials, network meta-analysis and literature, results showed patient time spent in clinical remission or response was highest when STELARA was used as a first-line advanced therapy for bio-naïve patients with moderately to severely acti...
Source: Johnson and Johnson - October 25, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news